M&A

Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon
Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon
Xconomy
gene therapy
M&A
Catalent
Paragon Bioservices
Flag link:
Is a Target and CVS Merger Now Inevitable?
Is a Target and CVS Merger Now Inevitable?
Motley Fool
CVS
Target
M&A
Flag link:
Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Fierce Pharma
AbbVie
Shire
taxes
tax inversions
M&A
Flag link:
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
CNBC
M&A
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Flag link:
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Here's Why Biohaven Pharmaceutical Jumped 20% Today
Here's Why Biohaven Pharmaceutical Jumped 20% Today
Motley Fool
Biohaven Pharmaceuticals
M&A
Flag link:
Syncona gene therapy start-ups Gyroscope, Orbit merge
Syncona gene therapy start-ups Gyroscope, Orbit merge
BioCentury
Syncona
Gyroscope
Orbit
gene therapy
retinal disease
M&A
Flag link:
It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready
It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready
Endpoints
Novartis
M&A
Alcon
Pharma CEOs
Vas Narasimhan
Flag link:
Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger
Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger
Endpoints
Histogenics
Ocugen
M&A
Flag link:
After Apotex founder's murder, family weighs sale worth up to $3B: report
After Apotex founder's murder, family weighs sale worth up to $3B: report
Fierce Pharma
Apotex
generics
Barry Sherman
M&A
Flag link:
1 Biotech That Biogen Should Buy ... but Probably Won't
1 Biotech That Biogen Should Buy ... but Probably Won't
Motley Fool
Biogen
Ionis Pharmaceuticals
M&A
Flag link:
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Endpoints
Bristol-Myers Squibb
Celgene
Morgan Stanley
M&A
Flag link:
Novartis CEO's $50 Billion of Deals Was Just the First Act
Novartis CEO's $50 Billion of Deals Was Just the First Act
Yahoo/Bloomberg
Novartis
M&A
Vas Narasimhan
Pharma CEOs
Flag link:
Is Walgreens CEO Pessina Opening Up To A Big Merger?
Is Walgreens CEO Pessina Opening Up To A Big Merger?
Forbes
Walgreens Boots Alliance
M&A
Flag link:
Roche must ask Spark shareholders once again to sell
Roche must ask Spark shareholders once again to sell
Biopharma Dive
Roche
Spark Therapeutics
gene therapy
M&A
Flag link:
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Boehringer Ingelheim buys MacroDel platform developer ICD Therapeutics
Pharmaceutical Business Review
Boehringer Ingelheim
MacroDel biologics
M&A
ICD Therapeutics
Flag link:
Smith & Nephew to acquire patient monitor dev Leaf Healthcare
Smith & Nephew to acquire patient monitor dev Leaf Healthcare
Mass Device
Smith & Nephew
patient monitoring
devices
Leaf Healthcare
M&A
Flag link:
Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Xconomy
Novartis
IFM Tre
M&A
anti-inflammatory
inflammation
Flag link:
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Starboard
Giovanni Caforio
Flag link:
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:

Pages